Erlotinib Tablets and Sodium Citrate and Citric Acid Oral Solution
Determining the interaction of Erlotinib Tablets and Sodium Citrate and Citric Acid Oral Solution and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Taking the erlotinib and sodium citrate doses too close together may interfere with the absorption of erlotinib and reduce its effectiveness. To prevent or minimize the interaction, sodium citrate should be taken at least 4 hours before or 2 hours after the daily dose of erlotinib. Contact your doctor if your condition worsens during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSING INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of erlotinib and reduce its concentrations in plasma. The solubility of erlotinib decreases when the pH is over 5, resulting in reduced absorption. Coadministration with the proton pump inhibitor omeprazole or the H2-receptor antagonist ranitidine has been found to significantly reduce the plasma concentrations of erlotinib. When coadministered with omeprazole, erlotinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 61% and 46%, respectively. When coadministered with ranitidine 300 mg, erlotinib Cmax and AUC decreased by 54% and 33%, respectively. The interaction has not been studied with antacids.
MANAGEMENT: If an antacid or other agent with acid-neutralizing effects is required during erlotinib therapy, it should be administered at least 4 hours before or 2 hours after the daily dose of erlotinib.
- "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA.
- Duong S, Leung M "Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents." J Oncol Pharm Pract 17 (2011): 448-52
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: erlotinib
Brand name: Tarceva
Synonyms: Erlotinib
Generic Name: citric acid / sodium citrate
Brand name: Bicitra, Cytra-2, Liqui-Dual Citra, Oracit, Shohl's Solution, Virtrate-2
Synonyms: Citric acid and sodium citrate, Sodium Citrate and Citric Acid
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Erlotinib Tablets-Sodium Citrate Anticoagulant Solution
- Erlotinib Tablets-Sodium Diuril
- Erlotinib Tablets-Sodium Edecrin
- Erlotinib Tablets-Sodium Ferric Gluconate
- Erlotinib Tablets-Sodium ferric gluconate complex
- Erlotinib Tablets-Sodium ferric gluconate complex Intravenous
- Sodium Citrate and Citric Acid Oral Solution-Errin
- Sodium Citrate and Citric Acid Oral Solution-Ertapenem
- Sodium Citrate and Citric Acid Oral Solution-Ertapenem Injection
- Sodium Citrate and Citric Acid Oral Solution-Ertapenem Sodium
- Sodium Citrate and Citric Acid Oral Solution-Ertugliflozin
- Sodium Citrate and Citric Acid Oral Solution-Ertugliflozin and metformin